Clinical Trials Browser

NCT02451696 2021-09-01

A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD

Phase 2 Completed

15 enrolled 9 charts

Focal Cortical Dysplasia, Epilepsy, Tuberous Sclerosis

NCT02860494 2021-05-03

EVEROST

Phase 2/3 Withdrawn

Tuberous Sclerosis

NCT01929642 2021-03-29

RAPT

Phase 2 Completed

3 enrolled 10 charts

Autistic Disorder, Tuberous Sclerosis, Self-Injurious Behavior

NCT02201212 2020-09-16

Everolimus for Cancer With TSC1 or TSC2 Mutation

Phase 2 Completed

30 enrolled 12 charts

Tuberous Sclerosis

NCT02061397 2020-08-25

SOS

Phase 1/2 Completed

10 enrolled 6 charts

Tuberous Sclerosis, Lymphangioleiomyomatosis

NCT01954693 2018-01-30

TRON

Phase 2 Unknown

48 enrolled

Tuberous Sclerosis

NCT01289912 2018-01-25

TSC

Phase 2 Completed

52 enrolled 12 charts

Autistic Disorder, Tuberous Sclerosis

NCT01070316 2017-03-13

Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)

Phase 1/2 Completed

20 enrolled 8 charts

Epilepsy, Hereditary Sensory and Autonomic Neuropathies, Tuberous Sclerosis

NCT01730209 2015-05-05

RAPIT

Phase 2/3 Unknown

60 enrolled

Autistic Disorder, Intellectual Disability, Tuberous Sclerosis

NCT00792766 2013-09-18

Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)

Phase 1/2 Completed

20 enrolled

Tuberous Sclerosis, Angiolipoma